Logotype for Heartbeam Inc

Heartbeam (BEAT) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Heartbeam Inc

Q3 2026 earnings summary

13 Nov, 2026

Executive summary

  • Heart attack assessment became the primary strategic focus, with FDA Breakthrough Device Designation, TAP acceptance and agreement on a 510(k) pathway advancing the program.

  • ALIGN-ACS showed comparable HeartBeam 3D ECG accuracy to standard 12-lead ECG; a U.S. pivotal study is planned to begin in Q1 2027.

  • Q3 losses, expenses and cash use declined; approximately $4.0M of Q4 ATM proceeds lifted unaudited pro forma cash to $10.1M.

  • The FDA-cleared system is limited to arrhythmia assessment; heart attack detection and AI applications remain investigational.

Financial highlights

  • Q3 operating expenses were $3.457M, down from $5.092M in Q2 2026 and $5.290M in Q3 2025; net loss was $3.010M versus $5.039M and $5.255M, respectively.

  • Q3 net loss per share was $0.05 versus $0.10 in Q2 2026 and $0.15 in Q3 2025; nine-month net loss was $12.749M versus $15.713M.

  • Nine-month operating expenses were $13.265M versus $15.829M; R&D was $6.816M versus $10.096M, while SG&A was $6.449M versus $5.733M.

  • No revenue was generated through September 30, 2026; no material commercial revenue is expected in 2026.

Outlook and guidance

  • FY2026 net operating cash outflow guidance is $12.0M–$12.5M, reduced from prior guidance of less than $14M; baseline Q4 operating cash outflow is expected below $2.5M.

  • Pivotal-study design is targeted for completion in Q4 2026, with enrollment planned for Q1 2027 and completion targeted by mid-2027; accelerated timing could increase Q4 spending.

  • Management described a likely pivotal study of about 300 patients across 8–10 centers; FDA agreement on study size and endpoints remains pending.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Heartbeam